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Abstract: 
*Purpose: Immunosuppression protocol for liver transplant (LT) varies between institutions and roles of 
induction immunosuppression in LT remain controversial. The aim of this study was to compare outcomes of 
primary LT patients based on the induction immunosuppression regimens, including thymoglobulin (rATG), 
basiliximab, and steroids. 
*Methods: We retrospectively reviewed medical charts of 166 patients who underwent LT alone from 2017 
through 2018 at a single institution. Patients were divided into three groups based on the type of induction 
immunosuppression utilized, and the outcomes were compared across groups. Survival was evaluated using 
the Kaplan-Meier method. Multivariable Cox regression was performed to identify potential predictors of post-
LT graft loss. Incidence of rejection was analyzed using Gray test by considering rejection episode and graft 
loss as competing risk events. 
*Results: During the study period, 56, 58, and 52 patients received rATG, basiliximab, and steroids only for 
induction immunosuppression. Tacrolimus, mycophenolate mofetil, and steroids were used for maintenance 
immunosuppression in all three groups. The age of the rATG group was significantly lower than the other two 
groups (P<0.001). The incidence rate of bacteremia (P=0.312), Clostridium difficile (P=0.779), 
Cytomegalovirus (P=0.903), Epstein-barr Virus (P=0.332), and fungemia (P=0.349) were similar across the 
three groups. Graft survival rate was significantly better in the rATG group compared to basiliximab (P=0.025) 
and solumedrol (P=0.003) (Figure a) After adjusting the risk by the patient’s age and MELD score utilizing a 
multivariate Cox regression analysis, rATG showed significantly lower risk of graft loss compared to the 
steroids group (hazard ratio 6.66, P=0.037), whereas risk was similar between the rATG and basiliximab 
groups (hazard ratio 3.99, P=0.111). Gray’s test showed no significant difference between the cumulative 
incidence rates of biopsy proven rejections between three groups (Figure b).  
  
*Conclusions: Patients undergoing LT alone with rATG for induction immunosuppression may have 
improved liver graft survival compared to patients who received basiliximab or steroids only. The risk of 
infection and incidence rates of biopsy proven rejection does not seem to be affected by induction 
immunosuppression regimens. Further studies are necessary to determine this relationship. 
